title: Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
abstract: BACKGROUND
  Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer.
  
  
  METHODS
  Pre-treatment core biopsies of patients from the GeparTrio neoadjuvant trial (NCT 00544765) were evaluated for MUC1 by immunohistochemistry (IHC; N = 691) and quantitative RT-PCR (qRT-PCR; N = 286) from formalin-fixed paraffin-embedded (FFPE) samples.
  
  
  RESULTS
  MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptor-positive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015).
  
  
  CONCLUSIONS
  MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker.
authors: Department of Pathology, Charité-Universitätsmedizin Berlin, Berlin. bruno.sinn@charite.de
authors: B V
authors: BV
authors: Sinn
authors: G
authors: G
authors: von Minckwitz
authors: C
authors: C
authors: Denkert
authors: H
authors: H
authors: Eidtmann
authors: S
authors: S
authors: Darb-Esfahani
authors: H
authors: H
authors: Tesch
authors: R
authors: R
authors: Kronenwett
authors: G
authors: G
authors: Hoffmann
authors: A
authors: A
authors: Belau
authors: C
authors: C
authors: Thommsen
authors: H J
authors: HJ
authors: Holzhausen
authors: S T
authors: ST
authors: Grasshoff
authors: K
authors: K
authors: Baumann
authors: K
authors: K
authors: Mehta
authors: M
authors: M
authors: Dietel
authors: S
authors: S
authors: Loibl
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D000077143:Docetaxel; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000235:genetics / Q000378:metabolism*; D020360:Neoadjuvant Therapy; D012333:RNA, Messenger / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013534:Survival; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C060192:MUC1 protein, human; D018396:Mucin-1; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: Mucin-1; breast cancer; neoadjuvant chemotherapy; pCR; prognosis